Sustained released intravitreal implants(University of Kentucky)
- Generic Name
- Sustained released intravitreal implants(University of Kentucky)
Inflammasome Therapeutics' K8 Implant Shows Promise in Geographic Atrophy Trial
• Inflammasome Therapeutics' K8 implant demonstrated a 66% reduction in geographic atrophy (GA) lesion growth at 3 months compared to untreated eyes in a small clinical trial.
• The K8 implant, a first-in-class dual inflammasome inhibitor, showed a positive safety profile with no drug-related serious adverse events reported during the initial phase.
• Based on these results, the trial has been expanded to include 30 patients (60 eyes) to further evaluate the safety and efficacy of K8 injections every 3 months.
• K8's unique mechanism of action targets multiple inflammatory pathways in GA, potentially offering improved efficacy compared to existing single-target therapies.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath